DDInter1867 DDInter817
A phenothiazine used as an antipsychotic agent and as an antiemetic.
Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression observed in other therapies. Gilteritinib was developed by Astellas Pharma and FDA approved on November 28, 2018. This drug was approved after being designed as an orphan drug with a fast track and priority review status.
Triflupromazine {u} (Compound) resembles {v} (Compound) Alimemazine
Alimemazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gilteritinib
Triflupromazine {u} (Compound) resembles {v} (Compound) Thioridazine
Thioridazine {u} may lead to a major life threatening interaction when taken with {v} Gilteritinib
Triflupromazine {u} (Compound) resembles {v} (Compound) Alimemazine
Alimemazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sulfamethoxazole
Sulfamethoxazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Gilteritinib
Triflupromazine {u} (Compound) resembles {v} (Compound) Trifluoperazine
Trifluoperazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Metronidazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Gilteritinib
Triflupromazine {u} (Compound) resembles {v} (Compound) Pipotiazine
Pipotiazine {u} (Compound) resembles {v} (Compound) Methotrimeprazine
Methotrimeprazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gilteritinib
Triflupromazine {u} (Compound) resembles {v} (Compound) Clomipramine
Clomipramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pentamidine
Pentamidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gilteritinib
Triflupromazine {u} (Compound) resembles {v} (Compound) Promazine
Promazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pentamidine
Pentamidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gilteritinib
Triflupromazine {u} (Compound) resembles {v} (Compound) Thioridazine
Thioridazine {u} may lead to a major life threatening interaction when taken with {v} Pentamidine
Pentamidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gilteritinib
Triflupromazine {u} (Compound) resembles {v} (Compound) Clomipramine
Clomipramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Triclabendazole
Triclabendazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gilteritinib
Triflupromazine {u} (Compound) resembles {v} (Compound) Desipramine
Desipramine {u} (Compound) resembles {v} (Compound) Promazine
Promazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gilteritinib
Triflupromazine (Compound) resembles Alimemazine (Compound) and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Triflupromazine (Compound) resembles Thioridazine (Compound) and Thioridazine may lead to a major life threatening interaction when taken with Gilteritinib
Triflupromazine (Compound) resembles Alimemazine (Compound) and Alimemazine may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Triflupromazine (Compound) resembles Trifluoperazine (Compound) and Trifluoperazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Triflupromazine (Compound) resembles Pipotiazine (Compound) and Pipotiazine (Compound) resembles Methotrimeprazine (Compound) and Methotrimeprazine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Triflupromazine (Compound) resembles Clomipramine (Compound) and Clomipramine may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Triflupromazine (Compound) resembles Promazine (Compound) and Promazine may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Triflupromazine (Compound) resembles Thioridazine (Compound) and Thioridazine may lead to a major life threatening interaction when taken with Pentamidine and Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Triflupromazine (Compound) resembles Clomipramine (Compound) and Clomipramine may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole and Triclabendazole may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Triflupromazine (Compound) resembles Desipramine (Compound) and Desipramine (Compound) resembles Promazine (Compound) and Promazine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib